📊 SNWV Key Takeaways
Is SANUWAVE Health, Inc. (SNWV) a Good Investment?
While SNWV demonstrates impressive revenue growth (+35% YoY) and exceptional profitability margins (77% gross, 27% net), severe structural financial distress undermines the investment case. Critical issue: interest coverage of 0.9x indicates the company cannot cover debt service from operating income, and a 13.52x debt-to-equity ratio reflects an unsustainable capital structure with minimal equity ($1.6M) relative to $21.9M long-term debt. The company depends on existing cash reserves and external financing for survival, creating significant default risk.
Why Buy SANUWAVE Health, Inc. Stock? SNWV Key Strengths
- Strong revenue growth of 35% YoY indicating market demand and business expansion
- Exceptional gross margin of 77% demonstrates pricing power and operational efficiency
- Positive free cash flow of $1.9M and $12M cash balance provides near-term liquidity buffer
- Net income growth of 135.7% YoY shows bottom-line improvement despite operational constraints
SNWV Stock Risks: SANUWAVE Health, Inc. Investment Risks
- Interest coverage ratio of 0.9x - operating income cannot service debt obligations, critical bankruptcy risk
- Extreme debt-to-equity ratio of 13.52x indicates leverage beyond sustainable levels for the revenue base
- Minimal equity cushion of $1.6M creates vulnerability to any operational setback or asset revaluation
- Deteriorating liquidity metrics (current ratio 1.38x, quick ratio 1.05x) suggest limited financial flexibility
- High debt burden of $21.9M relative to operating income of $4.9M creates refinancing dependency
Key Metrics to Watch
- Interest coverage ratio - must exceed 1.5x to indicate debt sustainability
- Operating cash flow trend - verify if positive OCF can be sustained and grow
- Debt reduction progress - monitor whether company can delever or refinance at reasonable rates
- Operating margin expansion - company needs 18-20%+ operating margins to justify debt load
- Cash runway - track monthly burn and time to profitability at current debt service levels
SANUWAVE Health, Inc. (SNWV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 4.4% FCF margin may limit capital allocation flexibility.
SNWV Profit Margin, ROE & Profitability Analysis
SNWV vs Healthcare Sector: How SANUWAVE Health, Inc. Compares
How SANUWAVE Health, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is SANUWAVE Health, Inc. Stock Overvalued? SNWV Valuation Analysis 2026
Based on fundamental analysis, SANUWAVE Health, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
SANUWAVE Health, Inc. Balance Sheet: SNWV Debt, Cash & Liquidity
SNWV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: SANUWAVE Health, Inc.'s revenue has grown significantly by 697% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.00 indicates the company is currently unprofitable.
SNWV Revenue Growth, EPS Growth & YoY Performance
SNWV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $9.3M | $5.7M | $0.38 |
| Q2 2025 | $7.1M | $1.1M | $0.01 |
| Q1 2025 | $5.7M | -$4.5M | $-0.66 |
| Q3 2024 | $4.8M | -$18.6M | $-5.92 |
| Q2 2024 | $4.4M | $2.0M | $0.00 |
| Q1 2024 | $3.5M | -$4.5M | $0.00 |
| Q3 2023 | $3.9M | -$1.1M | $0.00 |
| Q2 2023 | $3.5M | $1.6M | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
SANUWAVE Health, Inc. Dividends, Buybacks & Capital Allocation
SNWV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for SANUWAVE Health, Inc. (CIK: 0001417663)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_090458.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_090409.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_090425.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_090442.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_090447.xml | View → |
❓ Frequently Asked Questions about SNWV
What is the AI rating for SNWV?
SANUWAVE Health, Inc. (SNWV) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SNWV's key strengths?
Claude: Strong revenue growth of 35% YoY indicating market demand and business expansion. Exceptional gross margin of 77% demonstrates pricing power and operational efficiency.
What are the risks of investing in SNWV?
Claude: Interest coverage ratio of 0.9x - operating income cannot service debt obligations, critical bankruptcy risk. Extreme debt-to-equity ratio of 13.52x indicates leverage beyond sustainable levels for the revenue base.
What is SNWV's revenue and growth?
SANUWAVE Health, Inc. reported revenue of $44.1M.
Does SNWV pay dividends?
SANUWAVE Health, Inc. does not currently pay dividends.
Where can I find SNWV SEC filings?
Official SEC filings for SANUWAVE Health, Inc. (CIK: 0001417663) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SNWV's EPS?
SANUWAVE Health, Inc. has a diluted EPS of $0.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SNWV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, SANUWAVE Health, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SNWV stock overvalued or undervalued?
Valuation metrics for SNWV: ROE of 729.6% (sector avg: 15%), net margin of 26.8% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy SNWV stock in 2026?
Our dual AI analysis gives SANUWAVE Health, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is SNWV's free cash flow?
SANUWAVE Health, Inc.'s operating cash flow is $3.9M, with capital expenditures of $1.9M. FCF margin is 4.4%.
How does SNWV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 26.8% (avg: 12%), ROE 729.6% (avg: 15%), current ratio 1.38 (avg: 2).
Is SANUWAVE Health, Inc. carrying too much debt?
SNWV has a debt-to-equity ratio of 13.52x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.38 suggests adequate short-term liquidity.
Why is SNWV's return on equity (ROE) so high?
SANUWAVE Health, Inc. has a return on equity of 729.6%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 26.8% net margin.